Table 1.
Baseline BM patient and lesions characteristics between ABT and non-ABT cohorts
| Covariate | ABT (32 BM patients or 45 lesions) | No ABT (79 BM patients or 111 lesions) | P-value |
|---|---|---|---|
| Sex | |||
| Male | 15 (46.9%) | 31 (39.2%) | 0.460 |
| Female | 17 (53.1%) | 48 (60.8%) | |
| Active systemic disease | |||
| Yes | 17 (54.8%) | 35 (44.3%) | 0.319 |
| No | 14 (45.2%) | 44 (55.7%) | |
| Primary histology | |||
| Lung | 13 (40.6%) | 36 (32.9%) | 0.132 |
| Breast | 4 (12.5%) | 15 (19.0%) | |
| Melanoma | 5 (15.6%) | 18 (22.8%) | |
| RCC, GI, or other | 10 (31.3%) | 10 (12.7%) | |
| Age | |||
| ≤65 | 20 (62.5%) | 62 (78.5%) | 0.083 |
| >65 | 12 (37.5%) | 17 (21.5%) | |
| Number of BM | |||
| 1 | 20 (62.5%) | 60 (75.9%) | 0.153 |
| >1 | 12 (37.5%) | 19 (24.1%) | |
| Resected lesion | |||
| Yes | 34 (75.6%) | 81 (73.0%) | 0.740 |
| No | 11 (24.4%) | 30 (27.0%) | |
| Location of BM | |||
| Frontal/parietal/temporal | 32 (71.1%) | 64 (57.7%) | 0.118 |
| Occipital/cerebellum/brainstem | 13 (28.9%) | 47 (42.3%) | |
| Extracranial metastases | |||
| Yes | 10 (22.3%) | 21 (26.6%) | 0.552 |
| No | 21 (67.7%) | 58 (73.4%) | |
| ECOG | |||
| 0 | 5 (15.6%) | 25 (31.6%) | 0.175 |
| 1 | 18 (58.1%) | 40 (50.6%) | |
| 2+ | 9 (28.1%) | 14 (17.7%) | |
| GPA class | |||
| 0–1.0 | 1 (3.1%) | 1 (1.3%) | 0.033 |
| 1.5–2.5 | 23 (71.9%) | 39 (49.4%) | |
| 3.0–4.0 | 8 (25.0%) | 39 (49.4%) | |
| Number of fractions | |||
| 1 | 31 (68.9%) | 89 (80.2%) | 0.129 |
| >1 | 14 (31.1%) | 22 (19.8%) | |
| Prescribed dose, Gy | |||
| Mean | 21.3 | 19.9 | 0.118 |
| Median | 20.0 | 18.0 | |
| CTV volume (cc) | |||
| ≤ 4 | 13 (31.0%) | 31 (27.9%) | 0.808 |
| 4–14 | 17 (40.5%) | 36 (32.4%) | |
| > 14 | 12 (28.6%) | 34 (30.6%) | |
| PTV margin (mm) | |||
| 0–1 | 13 (28.9%) | 42 (37.8%) | 0.437 |
| 1.5 | 13 (28.9%) | 23 (20.7%) | |
| 2–2.5 | 19 (42.2%) | 46 (41.4%) | |
| Conformality index | |||
| Mean | 1.56 | 1.52 | 0.502 |
| Median | 1.50 | 1.47 | |
| Prescription IDL (%) | |||
| ≤80 | 19 (44.2%) | 44 (40.0%) | 0.636 |
| >80 | 24 (55.8%) | 66 (60.0%) |
Bold p values denotes statistical significant, p < 0.05
ABT angiotensin blockade therapy, RCC renal cell carcinoma, GI gastrointestinal, BM brain metastases, ECOG eastern cooperative oncology group, RPA recursive partitioning analysis, GPA graded prognostic assessment, Gy gray, CTV clinical target volume, PTV planning target volume, IDL isodose line